Implementing outcomes based managed entry agreements for rare disease treatments: nusinersen and tisagenlecleucel

10 August 2021 - Enthusiasm for the use of outcomes based managed entry agreements to manage uncertainties apparent at the time ...

Read more →

Optimising managed access: lessons from the Cancer Drugs Fund

14 May 2021 - The desire, opportunity, and willingness to increase access to potentially life saving cancer treatments has mounted in ...

Read more →

Determinants of managed entry agreements in the context of health technology assessment: a comparative analysis of oncology therapies in four countries

29 January 2021 - Managed entry agreements are increasingly used to address uncertainties arising in the health technology assessment process due ...

Read more →

Integrative review of managed entry agreements: chances and limitations

10 October 2020 - Managed entry agreements consist of a set of instruments to reduce the uncertainty and the budget impact ...

Read more →

The impact of managed entry agreements on pharmaceutical prices

6 July 2020 - Managed entry agreements have been used for several years, with the aim of curbing the growth of ...

Read more →

Managed Entry Agreements: policy analysis from the European perspective

21 April 2020 - This article begins with a short review of the existing taxonomy of managed entry agreements and includes ...

Read more →

Decision criteria that influence managed entry agreements

3 January 2019 - Managed entry agreements enable payers to subsidise access to new medicines while addressing uncertainties.  ...

Read more →

Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience

31 May 2018 - Innovative pricing agreements for medicines have been used in European markets for more than 20 years, ...

Read more →

The Australian Managed Entry Scheme: are we getting it right?

23 April 2018 - In 2010, the Australian Government introduced the managed entry scheme (MES) to improve patient access to subsidised ...

Read more →

A managed access approach to appraising new cancer drugs in England

12 January 2018 - The changing regulatory landscape brings new challenges to health technology assessment. Marketing authorisations are being granted as ...

Read more →

Characteristics of managed entry agreements in Australia

26 December 2017 - Australia relies on managed entry agreements for many medicines added to the national Pharmaceutical Benefits Scheme.  ...

Read more →

Access to Medicines Working Group communiques

8 September 2016 - The communiques from the February 2015, September 2015 and April 2016 meetings of the Access to Medicines ...

Read more →

New “managed access” process for Cancer Drugs Fund to go ahead, NHS England confirms

29 February 2016 - NHS England has confirmed that from 1 July its Cancer Drugs Fund will operate on a “managed ...

Read more →